Company profile for Bio-Path Holdings

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induc...
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4710 Bellaire Blvd Suite 210 Bellaire, TX 77401
Telephone
Telephone
(832) 742-1357
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/09/3095730/0/en/Bio-Path-Holdings-to-Present-at-Life-Sciences-Virtual-Investor-Forum.html

GLOBENEWSWIRE
09 Jun 2025

https://www.globenewswire.com/news-release/2025/06/03/3092581/0/en/Bio-Path-Holdings-Provides-Clinical-and-Operational-Update.html

GLOBENEWSWIRE
03 Jun 2025

https://www.globenewswire.com/news-release/2025/05/22/3087127/0/en/Bio-Path-Holdings-to-Host-Corporate-Update-Conference-Call-on-May-29-2025.html

GLOBENEWSWIRE
22 May 2025

https://www.globenewswire.com/news-release/2025/05/01/3072212/0/en/Bio-Path-Holdings-Achieves-Third-Pre-Clinical-Milestone-Confirming-Potential-of-BP1001-A-as-Treatment-for-Obesity-in-Type-2-Diabetes-Patients.html

GLOBENEWSWIRE
01 May 2025

https://www.globenewswire.com/news-release/2025/03/28/3051265/0/en/Bio-Path-Holdings-Reports-Full-Year-2024-Financial-Results.html

GLOBENEWSWIRE
28 Mar 2025

https://www.globenewswire.com//news-release/2025/03/18/3044334/0/en/Bio-Path-Holdings-Announces-Pre-Clinical-Results-Signaling-Increased-Potential-for-BP1001-A-as-Treatment-for-Obesity-in-Type-2-Diabetes-Patients.html

GLOBENEWSWIRE
18 Mar 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty